Prestige Brands Holdings, Inc.
Filed
Pursuant to Rule 424(b)(3)
Registration No. 333-139702
PROSPECTUS
14,973,785 Shares
Prestige Brands Holdings,
Inc.
Common Stock
Selling stockholders are offering 14,973,785 shares of our
common stock. All of the shares of common stock covered by this
prospectus are being offered and sold by the selling
stockholders. We are not selling any of the shares of common
stock offered by this prospectus and, therefore, will not
receive any of the proceeds from the sale of common stock by the
selling stockholders. We are registering the resale of the
shares of common stock to satisfy registration rights we
previously granted the selling stockholders. The registration
rights agreement requires that we pay substantially all the
expenses that are incurred in connection with registering this
offering.
You should carefully read this prospectus and any information
incorporated by reference into this prospectus before you decide
to invest in our common stock.
Our common stock is traded on the New York Stock Exchange under
the symbol PBH. On August 7, 2008, the last
reported sale price of our common stock on the New York Stock
Exchange was $10.19 per share. You are encouraged to obtain
a current quote for our stock.
See Risk Factors on page 4 of this prospectus to
read about factors you should consider before buying our common
stock.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus is August 8, 2008
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
Prospectus Summary
|
|
|
1
|
|
Risk Factors
|
|
|
4
|
|
Cautionary Statement Regarding Forward-Looking Statements
|
|
|
4
|
|
Use of Proceeds
|
|
|
4
|
|
Price Range of Common Stock
|
|
|
5
|
|
Dividend Policy
|
|
|
5
|
|
Selling Stockholders
|
|
|
5
|
|
Plan of Distribution
|
|
|
7
|
|
Legal Matters
|
|
|
8
|
|
Experts
|
|
|
8
|
|
Incorporation of Documents by Reference
|
|
|
8
|
|
Where You Can Find More Information
|
|
|
9
|
|
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement that we
filed with the Securities and Exchange Commission, or the SEC.
We were required by an agreement with the selling stockholders
to file this registration statement in order for the selling
stockholders to be able to sell the common stock offered by this
prospectus.
No person is authorized to give any information or represent
anything not contained in this prospectus and the documents
incorporated by reference in this prospectus. You should rely
only on the information contained in or incorporated by
reference into this prospectus. The information contained in
this prospectus or in any document incorporated by reference is
accurate only as of its date, regardless of the time of delivery
of this prospectus or any sale of common stock. Our business,
financial condition, results of operations and prospects may
have changed since that date.
This prospectus is not an offer to sell or solicitation of an
offer to buy these shares of common stock in any circumstances
under which or jurisdiction in which the offer or solicitation
is unlawful.
The terms Prestige, we, us,
and our as used in this prospectus refer to Prestige
Brands Holdings, Inc. and its consolidated subsidiaries and,
unless the context requires otherwise, their respective
predecessors.
Our fiscal year ends on March 31 of each year. References to a
year (e.g., 2008) refer to our fiscal year that ends
on March 31 of that year.
Trademarks and trade names used in this prospectus are the
property of Prestige or its subsidiaries, as the case may be. We
have utilized the
®
symbol the first time each federally registered trademark, owned
by Prestige or its subsidiaries, appears in this prospectus.
MARKET
INFORMATION
Information regarding market share, market position and industry
data pertaining to our business contained in or incorporated by
reference into this prospectus consists of estimates based on
data and reports compiled by industry professional organizations
(including Information Resources, Inc.) and analysts, and our
knowledge of our revenues and markets.
We take responsibility for compiling and extracting, but have
not independently verified, market and industry data provided by
third parties, or by industry or general publications, and take
no further responsibility for such data. Similarly, while we
believe our internal estimates are reliable, our estimates have
not been verified by any independent sources, and we cannot
assure you as to their accuracy.
i
PROSPECTUS
SUMMARY
The following summary should be read in conjunction with, and
is qualified in its entirety by, the more detailed information,
including the information under Risk Factors and
financial statements and related notes incorporated by reference
into this prospectus. Because this is a summary, it is not
complete and may not contain all of the information that is
important to you and that you should consider before buying
shares of our common stock. Our actual results could differ
materially from those anticipated in certain forward-looking
statements contained in or incorporated by reference into this
prospectus as a result of various factors, including those set
forth under Risk Factors in our periodic reports
that we file with the SEC.
Overview
We sell well-recognized, brand name
over-the-counter
healthcare, household cleaning and personal care products in a
global marketplace. We operate in niche segments of these
categories, which we believe are typically overlooked by larger
competitors. We view our established retail distribution
network, a low-cost operating model and our experienced
management team as a competitive advantage that we believe will
enable us to profitably grow our presence in these niche
segments. Our major brands, set forth in the table below, have
strong levels of consumer awareness and retail distribution
across all major channels of distribution. These brands
accounted for approximately 94.3% of our net sales for 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Market
|
|
|
|
|
Market
|
|
|
|
|
Major Brands
|
|
Position (1)
|
|
|
Market Segment
|
|
Share (1)
|
|
|
ACV(1)
|
|
|
|
|
|
|
|
|
(%)
|
|
|
(%)
|
|
|
Over-the-Counter
Drug:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chloraseptic®
|
|
|
#1
|
|
|
Sore Throat Relief
|
|
|
42.9
|
%
|
|
|
96
|
%
|
Clear
eyes®
|
|
|
#2
|
|
|
Eye Redness Relief
|
|
|
15.5
|
|
|
|
88
|
|
Compound
W®
|
|
|
#2
|
|
|
Wart Removal
|
|
|
33.4
|
|
|
|
90
|
|
Wartner®
|
|
|
#3
|
|
|
Wart Removal
|
|
|
10.2
|
|
|
|
60
|
|
The
Doctors®
NightGuardtm
|
|
|
#1
|
|
|
Bruxism (Teeth Grinding)
|
|
|
68.0
|
|
|
|
56
|
|
The
Doctors®
BrushPicks®
|
|
|
#2
|
|
|
Interdental Picks
|
|
|
21.9
|
|
|
|
47
|
|
Little
Remedies®(2)
|
|
|
N/A
|
|
|
Pediatric Healthcare
|
|
|
N/A
|
|
|
|
81
|
|
Murine®
|
|
|
#1
|
|
|
Personal Ear Care
|
|
|
21.3
|
|
|
|
72
|
|
New-Skin®
|
|
|
#1
|
|
|
Liquid Bandages
|
|
|
46.6
|
|
|
|
81
|
|
Dermoplast®
|
|
|
#3
|
|
|
Pain Relief Sprays
|
|
|
15.5
|
|
|
|
63
|
|
Household Cleaning:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comet®
|
|
|
#2
|
|
|
Abrasive Tub and Tile Cleaner
|
|
|
31.1
|
|
|
|
99
|
|
Chore
Boy®
|
|
|
#1
|
|
|
Soap Free Metal Scrubbers
|
|
|
28.9
|
|
|
|
37
|
|
Spic and
Span®
|
|
|
#6
|
|
|
All Purpose Cleaner
|
|
|
3.9
|
|
|
|
65
|
|
Personal Care:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cutex®
|
|
|
#1
|
|
|
Nail Polish Remover
|
|
|
26.7
|
|
|
|
91
|
|
Denorex®
|
|
|
#6
|
|
|
Medicated Shampoo
|
|
|
1.7
|
|
|
|
44
|
|
|
|
|
(1)
|
|
Source: Information Resources, Inc.
Market share and market position are
based on sales dollars in the United States, as calculated by
Information Resources for the 52 weeks ended March 23,
2008 in food stores, drug stores, and mass merchandisers
(excluding Wal-Mart). Market Segment has been
defined by the Company based upon its product offerings and the
categories in which it competes. ACV refers to the
All Commodity Volume Food Drug Mass Index, as calculated by
Information Resources for the 52 weeks ended March 23,
2008. ACV measures the weighted sales volume of stores that sell
a particular product out of all the stores that sell products in
that market segment generally. For example, if a product is sold
by 50% of the stores that sell products in that market segment,
but those stores account for 85% of the sales volume in that
market segment, that product would have an ACV of 85%. We
believe that ACV is a measure of a products importance to
major retailers. We believe that a high ACV evidences a
products attractiveness to consumers, as major national
and regional retailers will carry products that are attractive
to their customers. Lower ACV measures would indicate that a
product is not as available to consumers because the major
retailers do not carry products for which consumer demand may
not be as high. For these reasons, we believe that ACV is an
important measure for investors to gauge consumer awareness of
our product offerings.
|
|
(2)
|
|
Market share information for market
segments in which Little Remedies products compete is not
available from Information Resources.
|
1
Our products are sold through multiple channels, including mass
merchandisers and drug, grocery, dollar and club stores. This
channel mix allows us to effectively launch new products across
all distribution channels and reduce our exposure to any single
distribution channel. We focus our internal resources on
marketing, sales, customer service and product development.
While we perform the production planning and oversee the quality
control aspects of the manufacturing, warehousing and
distribution of our products, we outsource the operating
elements of these functions to entities that offer expertise in
these areas and cost efficiencies due to economies of scale.
This operating model allows us to focus our marketing and
product development, which we believe enables us to achieve
attractive margins while minimizing capital expenditures and
working capital requirements.
We have developed our brand portfolio by acquiring strong and
well-recognized brands from larger consumer products and
pharmaceutical companies, as well as other brands from smaller
private companies. While the brands we have purchased from
larger consumer products and pharmaceutical companies have long
histories of support and brand development, we believe that at
the time we acquired them they were considered
non-core by their previous owners and did not
benefit from the focus of senior level management or strong
marketing support. We believe that the brands we have purchased
from smaller private companies have been constrained by the
limited resources of their prior owners. After acquiring a
brand, we seek to increase its sales, market share and
distribution in both new and existing channels through our
established retail distribution network. We pursue this growth
through increased advertising and promotion, new marketing
strategies, improved packaging and formulations and innovative
new products.
Our Brand
History
We were originally formed in 1996 as a joint venture of Medtech
Labs and The Shansby Group to acquire
over-the-counter
drug brands from American Home Products. Since 2001, our
portfolio of brand name products has expanded from
over-the-counter
healthcare to include household cleaning and personal care
products. We have added brands to our portfolio principally by
acquiring strong and well-recognized brands from larger consumer
products and pharmaceutical companies. In February 2004, GTCR
Golder Rauner II, LLC (GTCR), a private equity firm,
acquired our business. In addition, we acquired the Spic and
Span business in March 2004.
In April 2004, we acquired Bonita Bay Holdings, Inc., which
conducted its business under the Prestige name.
After we completed the Bonita Bay acquisition, we began to
conduct our business under the Prestige name. The
Bonita Bay brand portfolio included Chloraseptic, Comet,
Clear eyes and Murine.
In October 2004, we acquired the Little Remedies brand of
pediatric
over-the-counter
healthcare products, through our purchase of Vetco, Inc.
Products offered under the Little Remedies brand include
Little
Noses®
nasal products, Little
Tummys®
digestive health products, Little
Colds®
cough/cold remedies and Little Remedies New Parents
Survival Kits. The Little Remedies products deliver
relief of common childhood ailments without unnecessary
additives such as saccharin, alcohol, artificial flavors,
coloring dyes or harmful preservatives.
In October 2005, we acquired the Chore
Boy® brand
of metal cleaning pads, scrubbing sponges, and non-metal soap
pads. The brand has over 84 years of history in the
scouring pad and cleaning accessories categories.
In November 2005, we acquired Dental Concepts LLC, a marketer of
therapeutic oral care products sold under The
Doctors®
brand. The business is driven primarily by two niche segments,
bruxism (nighttime teeth grinding) and interdental cleaning. Its
products include The
Doctors®
NightGuardTM
brand dental protector, the first
FDA-cleared
over-the-counter treatment for bruxism and The
Doctors®
BrushPicks®
which are disposable interdental toothpicks.
In September, 2006, we acquired Wartner USA B.V., the owner of
the
Wartner®
brand of
over-the-counter
wart treatment products. Wartner is the #3 brand in the U.S.
over-the-counter
wart treatment category. Although we made no strategic
acquisitions in our fiscal year ended March 31, 2008, we
repaid $52.1 million of our senior debt with cash flow
generated from operations. This followed $26.4 million in
debt reduction during the second half of the prior fiscal year.
These debt repayments reduce our interest costs on a
going-forward basis, and favorably affect our interest coverage
and our debt-to-equity ratios.
Corporate
Information
Our principal executive office is located at 90 North Broadway,
Irvington, New York 10533, and our telephone number is
(914) 524-6810.
Our website is www.prestigebrandsinc.com. Information on our
website is not a part of this prospectus and is not incorporated
in this prospectus by reference.
2
THE
OFFERING
|
|
|
Common stock offered by the selling stockholders |
|
14,973,785 shares |
|
Selling Stockholder |
|
The shares being offered by this prospectus are owned in the
aggregate by GTCR Fund VIII, L.P. (Fund VIII), GTCR
Fund VIII/B, L.P. (Fund VIII/B), GTCR Co-Invest II,
L.P. (Co-Invest II) and GTCR Capital Partners, L.P.
(Capital Partners) (collectively, the GTCR
Funds). The address of each entity comprising the GTCR
Funds is c/o GTCR Golder Rauner, L.L.C., 6100 Sears Tower,
Chicago, Illinois 60606. Two of our directors, David A. Donnini
and Vincent J. Hemmer, are principals of GTCR. |
|
Common stock to be outstanding after this offering |
|
49,940,765 shares |
|
Use of proceeds |
|
We will not receive any proceeds from the sale of shares of our
common stock by the selling stockholders. |
|
Dividends |
|
We have not in the past paid, and do not expect for the
foreseeable future, to pay dividends on our common stock.
Instead, we anticipate that all of our earnings in the
foreseeable future will be used in the operation and growth of
our business. Any future determination to pay dividends will be
at the discretion of our board of directors and will depend
upon, among other factors, our results of operations, financial
condition, capital requirements and contractual restrictions,
including restrictions under our then existing debt instruments,
and any other considerations our board of directors deems
relevant. |
|
Risk Factors |
|
Investing in our common stock involves substantial risks. You
should carefully read and consider the information set forth
under Risk Factors and all other information
contained in or incorporated by reference into this prospectus
before investing in our common stock. |
|
New York Stock Exchange symbol |
|
PBH |
The number of shares of common stock to be outstanding after
this offering is based on the number of shares outstanding as of
July 31, 2008.
3
RISK
FACTORS
An investment in our securities is risky. Before making a
decision about investing in our securities, you should read and
consider carefully the risk factors and information contained in
our periodic reports filed with the SEC, which are incorporated
by reference in this prospectus. Additional risks and
uncertainties not presently known to us or that we currently
deem immaterial may also impair our business operations. If any
of the risks or uncertainties described in our periodic reports
filed with the SEC or any such additional risks and
uncertainties actually occur, our business, results of
operations and financial condition could be materially and
adversely affected. In that case, the trading price of the
securities being offered by this prospectus and any applicable
prospectus supplement could decline, and you might lose all or
part of your investment. You should consider these risk factors
when you read forward-looking statements contained elsewhere or
incorporated by reference in this prospectus.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained and incorporated by reference
in this prospectus and in particular, statements found under the
captions Risk Factors and Managements
Discussion and Analysis of Financial Condition and Results of
Operations in our Annual Report on
Form 10-K
for the year ended March 31, 2008 that are not historical
in nature may constitute forward-looking statements within the
meaning of Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act of 1934 (the
Exchange Act). We intend such forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995, and we are including this
statement for purposes of invoking these safe harbor provisions.
These forward-looking statements, which are based on certain
assumptions and describe our future plans, strategies and
expectations on revenue growth, expansion opportunities,
strategic acquisitions, operating costs and expenses, and
industry trends, are generally identifiable by use of the words
believe, expect, intend,
anticipate, estimate,
forecast, project, plan,
will continue, will likely result or
similar expressions. Our ability to predict the results or the
actual effect of future plans or strategies is inherently
uncertain. Our actual results could differ materially from those
indicated in these statements as a result of matters discussed
herein, as well as certain risk factors more fully discussed
under Risk Factors in our periodic reports filed
with the SEC.
Because actual results may differ from those predicted by such
forward-looking statements, you should not rely on such
forward-looking statements when deciding whether to buy, sell or
hold our securities. We undertake no obligation to update these
forward-looking statements in the future.
USE OF
PROCEEDS
We will not receive any proceeds from the sale of shares of our
common stock by the selling stockholders.
We, however, as required by the registration rights agreement
between us and the selling stockholders, will pay substantially
all of the costs, fees and expenses incurred in effecting the
registration of the shares of common stock covered by this
prospectus, including, but not limited to, all registration and
filing fees, fees and expenses of our counsel and our
accountants and reasonable fees and expenses of counsel to the
selling stockholders. The selling stockholders will pay any
brokerage expenses incurred by the selling stockholders in
connection with their sales of common stock.
4
PRICE
RANGE OF COMMON STOCK
Our common stock is listed on the New York Stock Exchange under
the symbol PBH. Public trading of our common stock
commenced on February 10, 2005. Prior to that date, there
was no public trading market for our common stock.
The following table sets forth the high and low closing prices
per share for our common stock as reported on the New York Stock
Exchange for each fiscal quarter during our last two fiscal
years (2007 and 2008) and for the first quarter of the 2009
fiscal year. You are encouraged to obtain a current quote for
our stock.
|
|
|
|
|
|
|
|
|
Fiscal Year Ending March 31, 2007
|
|
High
|
|
|
Low
|
|
|
First quarter ended June 30, 2006
|
|
$
|
12.90
|
|
|
$
|
8.25
|
|
Second quarter ended September 30, 2006
|
|
$
|
11.55
|
|
|
$
|
8.50
|
|
Third quarter ended December 31, 2006
|
|
$
|
13.87
|
|
|
$
|
10.77
|
|
Fourth quarter ended March 31, 2007
|
|
$
|
13.53
|
|
|
$
|
10.80
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ending March 31, 2008
|
|
|
|
|
|
|
|
First quarter ended June 30, 2007
|
|
$
|
13.60
|
|
|
$
|
11.20
|
|
Second quarter ended September 30, 2007
|
|
$
|
13.67
|
|
|
$
|
10.23
|
|
Third quarter ended December 31, 2007
|
|
$
|
11.43
|
|
|
$
|
7.47
|
|
Fourth quarter ended March 31, 2008
|
|
$
|
8.58
|
|
|
$
|
6.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ending March 31, 2009
|
|
|
|
|
|
|
|
First quarter ended June 30, 2008
|
|
$
|
11.93
|
|
|
$
|
8.08
|
|
On August 7, 2008, the last reported sale price of our
common stock on the New York Stock Exchange was $10.19 per
share. As of July 31, 2008, there were approximately 54
holders of record of our common stock.
DIVIDEND
POLICY
We have not in the past paid, and do not expect for the
foreseeable future, to pay dividends on our common stock.
Instead, we anticipate that all of our earnings in the
foreseeable future will be used in the operation and growth of
our business. Any future determination to pay dividends will be
at the discretion of our board of directors and will depend
upon, among other factors, our results of operations, financial
condition, capital requirements and contractual restrictions,
including restrictions under our then existing debt instruments,
and any other considerations our board of directors deems
relevant.
SELLING
STOCKHOLDERS
The
GTCR Entities
The shares being offered by this prospectus are owned in the
aggregate by GTCR Fund VIII, L.P.
(Fund VIII), GTCR Fund VIII/B, L.P.
(Fund VIII/B), GTCR Co-Invest II, L.P.
(Co-Invest II) and GTCR Capital Partners, L.P.
(Capital Partners) (collectively, the GTCR
entities). The address of each entity comprising the GTCR
entities is
c/o GTCR
Golder Rauner, L.L.C., 6100 Sears Tower, Chicago, Illinois 60606.
In connection with our initial public offering in 2005, we were
reorganized as a corporation pursuant to an exchange agreement
whereby our initial investors, which included the GTCR entities,
exchanged their common units in one of our predecessor entities
for our common stock. These transactions resulted in ownership
by the GTCR entities of the shares being offered in this
prospectus.
Two of our directors, David A. Donnini and Vincent J. Hemmer,
are principals of GTCR. Except for that relationship, none of
the selling shareholders has or, within the last three years,
has had any position, office or other material relationship with
us or any of our affiliates beyond their investment in, or
receipt of, our securities.
5
Under a registration rights agreement entered into at the time
of our reorganization mentioned above, the GTCR entities have
the right at any time, subject to specified conditions, to
request us to register, at our expense, any or all of their
securities under the Securities Act. Accordingly, we have filed
the registration statement of which this prospectus is a part at
the request of the GTCR entities so that they may engage in open
market sales of our shares that they currently own.
The GTCR entities currently own 14,973,785 (approximately 30%)
shares of our common stock. The number of shares of our common
stock owned by each of the affiliated GTCR entities is as
follows:
|
|
|
|
|
Affiliated Entity
|
|
Shares of Common Stock
|
|
|
GTCR Fund VIII, L.P.
|
|
|
12,347,774
|
|
GTCR Fund VIII/B, L.P.
|
|
|
2,166,976
|
|
GTCR Co-Invest II, L.P.
|
|
|
65,904
|
|
GTCR Capital Partners, L.P.
|
|
|
393,131
|
|
David A. Donnini, one of our directors, has voting or investment
control over the securities owned by each selling stockholder.
Assuming that the GTCR entities sell all of the shares offered
by this prospectus, they will own none of our common stock.
Corporate
Opportunities and Transactions with GTCR
In recognition that directors, officers, stockholders, members,
managers
and/or
employees of the GTCR entities may serve as our directors
and/or
officers, and that the GTCR entities and our other non-employee
directors may engage in similar activities or lines of business
that we do, our amended and restated certificate of
incorporation provides for the allocation of certain corporate
opportunities between us and such persons. Specifically, subject
to applicable law, neither the GTCR entities nor any of our
non-employee directors have any duty to refrain from engaging
directly or indirectly in the same or similar business
activities or lines of business that we do. In the event that
any GTCR entity or non-employee director acquires knowledge of a
potential transaction or matter which may be a corporate
opportunity for such persons and us, we do not have any
expectancy in such corporate opportunity, and such persons do
not have any duty to communicate or offer such corporate
opportunity to us and may pursue or acquire such corporate
opportunity for themselves or direct such opportunity to another
person. In addition, if any GTCR entity or non-employee director
acquires knowledge of a potential transaction or matter which
may be a corporate opportunity for us and such person, we do not
have any expectancy in such corporate opportunity unless such
corporate opportunity is expressly offered to such person solely
in his or her capacity as a director or officer of our company.
In recognition that we may engage in material business
transactions with the GTCR entities, from which we are expected
to benefit, our amended and restated certificate of
incorporation provides that any of our directors or officers who
are also directors, officers, stockholders, members, managers
and/or
employees of any GTCR entity will have fully satisfied and
fulfilled his or her fiduciary duty to us and our stockholders
with respect to such transaction, if:
|
|
|
|
|
the transaction was approved, after being made aware of the
material facts of the relationship between each of Prestige or a
subsidiary thereof and the GTCR entity and the material terms
and facts of the transaction, by (i) an affirmative vote of
a majority of the members of our board of directors who do not
have a material financial interest in the transaction
(Interested Persons) or (ii) an affirmative
vote of a majority of the members of a committee of our board of
directors consisting of members who are not Interested
Person; or
|
|
|
|
the transaction was fair to us at the time we entered into the
transaction; or
|
|
|
|
the transaction was approved by an affirmative vote of the
holders of a majority of shares of our common stock entitled to
vote generally in the election of directors, voting together as
a single class, excluding the GTCR entities and any Interested
Person.
|
Any amendment to the foregoing provisions of our amended and
restated certificate of incorporation requires the affirmative
vote of at least 80% of the voting power of all shares of our
common stock then outstanding.
6
PLAN OF
DISTRIBUTION
The shares covered by this prospectus may be offered and sold
from time to time by the selling stockholders. The term
selling stockholder includes pledgees, donees,
transferees or other successors in interest selling shares
received after the date of this prospectus from each selling
stockholder as a pledge, gift, partnership distribution or other
non-sale related transfer. The number of shares beneficially
owned by a selling stockholder will decrease as and when it
effects any such transfers. The plan of distribution for the
selling stockholders shares sold hereunder will otherwise
remain unchanged, except that the transferees, pledgees, donees
or other successors will be selling stockholders hereunder. To
the extent required, we may amend and supplement this prospectus
from time to time to describe a specific plan of distribution.
The selling stockholders will act independently of us in making
decisions with respect to the timing, manner and size of each
sale. The selling stockholders may make these sales at prices
and under terms then prevailing or at prices related to the then
current market price. The selling stockholders may also make
sales in negotiated transactions. The selling stockholders may
offer their shares from time to time pursuant to one or more of
the following methods:
|
|
|
|
|
ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers;
|
|
|
|
one or more block trades in which the broker-dealer will attempt
to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction;
|
|
|
|
purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;
|
|
|
|
an exchange distribution in accordance with the rules of the
applicable exchange;
|
|
|
|
privately negotiated transactions;
|
|
|
|
through underwriters, brokers or dealers (who may act as agents
or principals) or directly to one or more purchasers;
|
|
|
|
settlement of short sales entered into after the effective date
of the registration statement of which this prospectus is a part;
|
|
|
|
broker-dealers may agree with the selling stockholders to sell a
specified number of such shares at a stipulated price per share;
|
|
|
|
through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise;
|
|
|
|
a combination of any such methods of sale; and
|
|
|
|
any other method permitted pursuant to applicable law.
|
In addition to the foregoing methods, the selling stockholders
may offer their shares from time to time in transactions
involving principals or brokers not otherwise contemplated
above, in a combination of such methods described above or any
other lawful methods. The selling stockholders may also
transfer, donate or assign their shares to lenders, family
members and others and each of such persons will be deemed to be
a selling stockholder for purposes of this prospectus. The
selling stockholders or their successors in interest may from
time to time pledge or grant a security interest in some or all
of the shares of common stock, and if the selling stockholders
default in the performance of their secured obligations, the
pledgees or secured parties may offer and sell the shares of
common stock from time to time under this prospectus; provided,
however, in the event of a pledge or then default on a secured
obligation by the selling stockholder, in order for the shares
to be sold under this registration statement, unless permitted
by law, we must distribute a prospectus supplement and/or
amendment to this registration statement amending the list of
selling stockholders to include the pledgee, secured party or
other successors in interest of the selling stockholder under
this prospectus.
The selling stockholders may also sell their shares pursuant to
Rule 144 under the Securities Act, which permits limited
resale of shares subject to the satisfaction of certain
conditions, including, among other things, the availability of
certain current public information concerning the issuer, the
resale occurring following the required
7
holding period under Rule 144 and the number of shares
being sold during any three-month period not exceeding certain
limitations.
Sales through brokers may be made by any method of trading
authorized by any stock exchange or market on which the shares
may be listed or quoted, including block trading in negotiated
transactions. Without limiting the foregoing, such brokers may
act as dealers by purchasing any or all of the shares covered by
this prospectus, either as agents for others or as principals
for their own accounts, and reselling such shares pursuant to
this prospectus. The selling stockholders may effect such
transactions, directly or indirectly, through underwriters,
broker-dealers or agents acting on their behalf. In effecting
sales, broker-dealers or agents engaged by the selling
stockholders may arrange for other broker-dealers to
participate. Broker-dealers or agents may receive commissions,
discounts or concessions from the selling stockholders, in
amounts to be negotiated immediately prior to the sale (which
compensation as to a particular broker-dealer might be in excess
of customary commissions for routine market transactions).
In offering the shares covered by this prospectus, the selling
stockholders, and any broker-dealers and any other participating
broker-dealers who execute sales for the selling stockholders,
may be deemed to be underwriters within the meaning
of the Securities Act in connection with these sales. Any
profits realized by the selling stockholders and the
compensation of such broker-dealers may be deemed to be
underwriting discounts and commissions.
Our common stock is traded on the New York Stock Exchange under
the symbol PBH.
We, as required by the registration rights agreement between us
and the selling shareholders, will pay substantially all of the
costs, fees and expenses incurred in effecting the registration
of the shares of common stock covered by this prospectus,
including, but not limited to, all registration and filing fees,
fees and expenses of our counsel and our accountants and
reasonable fees and expenses of counsel to the selling
stockholders.
LEGAL
MATTERS
The validity of the common stock offered by this prospectus will
be passed upon for us by Baker, Donelson, Bearman,
Caldwell & Berkowitz, PC, Nashville, Tennessee.
EXPERTS
The financial statements and managements assessment of the
effectiveness of internal control over financial reporting
(which is included in Managements Annual Report on
Internal Control over Financial Reporting) incorporated in this
prospectus by reference to the Annual Report on
Form 10-K
for the year ended March 31, 2008, have been so
incorporated in reliance on the report of PricewaterhouseCoopers
LLP, an independent registered public accounting firm, given on
the authority of said firm as experts in auditing and accounting.
INCORPORATION
OF DOCUMENTS BY REFERENCE
The SEC allows us to incorporate by reference
certain of our publicly filed documents into this prospectus,
which means that important information included in such publicly
filed documents is considered part of this prospectus. The
following documents filed by us with the SEC, and any future
documents we file with the SEC under Sections 13(a), 13(c), 14
or 15(d) of the Exchange Act prior to the termination of the
offering, are incorporated by reference into this prospectus:
|
|
|
|
|
our annual report on
Form 10-K
for the fiscal year ended March 31, 2008;
|
|
|
|
our current reports on
Form 8-K
filed on May 15, 2008, May 19, 2008 and August 7,
2008 (Item 8.01 only) (specifically excluding the
information furnished under Items 2.02 or 7.01 and the
exhibits furnished thereto); and
|
|
|
|
the description of our common stock contained in our
Form 8-A
filed with the SEC on February 10, 2005.
|
8
Any statement contained in a document incorporated or deemed to
be incorporated by reference in this prospectus will be deemed
to be modified or superseded for the purposes of this prospectus
to the extent that a later statement contained herein or in any
other document incorporated or deemed to be incorporated by
reference in this prospectus modifies or supersedes the earlier
statement. Any statement so modified or superseded will not be
deemed, except as so modified or superseded, to constitute a
part of this prospectus.
We will provide at no cost to each person, including any
beneficial owner, to whom this prospectus is delivered, upon
oral or written request of such person, a copy of any or all of
the reports or documents that have been incorporated by
reference in this prospectus, but not delivered with the
prospectus, other than exhibits to such other documents (unless
such exhibits are specifically incorporated by reference into
such documents). We will furnish any exhibit upon the payment of
a specified reasonable fee, which fee will be limited to our
reasonable expenses in furnishing such exhibit. Requests for
such copies should be directed to:
Charles N. Jolly, Esq.
General Counsel and Secretary
Prestige Brands Holdings, Inc.
90 North Broadway
Irvington, New York 10533
Telephone:
(914) 524-6810
These documents may also be accessed through our internet web
site at www.prestigebrandsinc.com or as described under
Where You Can Find More Information.
WHERE YOU
CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement under the
Securities Act with respect to this offering. This prospectus,
which forms a part of the registration statement, does not and
is not required to contain all the information included in the
registration statement and the exhibits and schedules to the
registration statement. For further information about us and our
common stock, you should refer to the registration statement and
its exhibits and schedules. This prospectus summarizes
provisions that we consider material of certain contracts and
other documents to which we refer you. Because any summary may
not contain all of the information that you find important, you
should review the full text of those documents. We have included
copies of those documents as exhibits to the registration
statement, or have provided references to our other SEC filings
for a more complete understanding of the document or matter.
We also currently are subject to the information requirements of
the Exchange Act and in accordance therewith file periodic
reports, proxy statements and other information with the SEC.
You may read and copy (at prescribed rates) any such reports,
proxy statements and other information at the SECs Public
Reference Room at 100 F Street, N.E., Washington, D.C.
20549. For further information concerning the SECs Public
Reference Room, you may call the SEC at
1-800-SEC-0330.
This information may also be accessed on the World Wide Web
through the SECs Internet address at http://www.sec.gov.
Our filings may also be accessed on the World Wide Web through
our Internet address at http://www.prestigebrandsinc.com.
Information on our website is not a part of this prospectus and
is not incorporated in this prospectus by reference.
9
14,973,785 Shares
Prestige Brands Holdings,
Inc.
Common Stock
PROSPECTUS
August 8, 2008